Business Wire

Cumulocity Collaborates with Cisco to Streamline IoT Service and Application Delivery

Del

Cumulocity, a leading mobile application enablement platform, today announced a collaboration with Cisco Jasper, Cisco’s IoT Cloud Business Unit, which will enable enterprises to streamline the delivery of IoT services and applications through connected devices. This collaboration allows Cumulocity to integrate the functionality of the Cisco Jasper IoT service platform, making it easy for joint customers to manage the delivery of IoT services and applications on the Cisco Jasper platform from within Cumulocity.

“Our goal is to make it as simple as possible for enterprises to deliver and manage IoT services while working within their IT solutions of choice,” said Macario Namie, Head of IoT Strategy at Cisco Jasper. “This integration gives Cumulocity customers access to their Cisco Jasper IoT service platform, and all of the visibility, intelligence and control they need to manage their connected services, from within Cumulocity.”

“Over 3,500 enterprises rely on the Cisco Jasper platform to deliver their IoT services, and many of those enterprises already utilize Cumulocity’s powerful application enablement platform to create, deploy and manage IoT applications that facilitate control of devices and their data,” said Jari Salminen, MD Sales & Strategic Partners at Cumulocity. “This collaboration enables our existing joint customers to easily manage their IoT connectivity, devices and data within a single solution, while also streamlining the ability for new customers to bring IoT services and applications to market.”

Control Center is the Cisco Jasper IoT service platform, a cloud-based IoT platform that enables companies of all sizes to rapidly and cost-effectively launch, manage and monetize IoT services for any connected device. The platform, which is easily configurable to meet the unique requirements of businesses across a broad range of industries, helps companies accelerate time-to-market, automate operations, optimize performance, troubleshoot and fix issues, and manage costs.

The Cumulocity IoT application enablement platform is designed to facilitate an open eco-system with free and immediate access to test accounts, open developer documentation and tools. The Cumulocity platform is a Software-as-a-Service (SaaS) offering, which is sold through mobile operators and is extensible to enterprise end customers. Through this integration, mobile operators who resell Cumulocity services will have the benefit of having Control Center functionality built into the Cumulocity-based applications they make available to their enterprise customers.

As businesses grow, Control Center makes it easy for them to seamlessly scale their IoT service businesses across the globe. Cisco Jasper collaborates with 27 mobile operator groups, representing more than 100 mobile operator networks worldwide, to deliver the benefits of the Cisco Jasper IoT solutions.

About Cumulocity

Cumulocity is the leading independent Application Enablement and Device Management platform for the Internet-of-Things (IoT) – since 2010. Cumulocity is an open platform, delivered via cloud or on-premise, that provides a complete feature set for rapidly developing and deploying IoT solutions. The key features include Data collection and Storage, Real-Time Analytics, Real-Time Visualization and Device Management. Scalability, security and reliability are critical in IoT solutions. Our origins as part of Nokia Siemens Networks, the world's mobile broadband specialist, gives us the experience of securely managing millions of devices without service interruptions.

For more information and to start your free trial visit www.cumulocity.com.

About Cisco

Cisco is the worldwide leader in IT that helps companies seize the opportunities of tomorrow by proving that amazing things can happen when you connect the previously unconnected. For ongoing news, please go to http://newsroom.cisco.com.

Contact information

Cisco
Robb Henshaw
robhensh@cisco.com
+1 925-640-7321
or
Cumulocity
Jari Salminen
jari.salminen@cumulocity.com
+358 44 012 757

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers17.2.2018 21:00Pressemelding

Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im

CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 08:00Pressemelding

Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates

Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 18:26Pressemelding

Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a

General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 17:05Pressemelding

General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges

Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 09:03Pressemelding

Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o

Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 08:00Pressemelding

Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and